Shengtai Pharmaceutical Schedules 2008 Fourth Quarter And Year-End Financial Results and Conference Call
Mr. Qingtai Liu (Chief Executive Officer), Ms. Melody Shi (Chief FinancialOfficer), and Ms. Michelle Wang (Investor Relations Manager) will be theprimary speakers on the call.
A live webcast of the conference call will be available on the InvestorRelations page of Shengtai Pharmaceutical's web site athttp://shengtaipharmaceutical.com . Please visit the Web site at least 15minutes early to register for the webcast and download any necessary audiosoftware.
To participate, please call the following numbers ten minutes before thecall start time:
Phone Number + 1 (877) 407-8035 (North America)
Phone Number + 1 (201) 689-8035 (International)
A replay of the call will be available through Tuesday, October 7, 2008,at 11:59 P.M. Eastern Daylight Time/ Wednesday, October 8, 2008, 11:59 A.M.Beijing Time. For the replay, please call:
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary,Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chineseoperating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leadingmanufacturer and supplier of pharmaceutical grade glucose used for medicalpurposes. It also manufactures and supplies glucose and cornstarch productsto the food, beverage and industrial production industries in China. For moreinformation about Shengtai Pharmaceutical, Inc., please visithttp://shengtaipharmaceutical.com .
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995: Certain statements in this press release and oral statements made bythe Company constitute forward-looking statements for purposes of the safeharbor provisions under The Private Securities Litigation Reform Act of 1995.These statements include, without limitation, statements regarding our abilityto prepare the Company for growth, the Company's planned capacity expansion in2008 and predictions and guidance relating to the Company's future financialperformance. We have based these forward-looking statements largely on ourcurrent expectations and projections about future events and financial trendsthat we believe may affect our financial condition, results of operations,business strategy and financial needs, but they involve risks anduncertainties that could cause actual results to differ materially from thosein the forward-looking statements, which may include, but are not limited to,such factors as unanticipated changes in product demand especially in thepharmaceutical industry, pricing and demand trends for the Company's products,changes to government regulations, risk associated with operation of theCompany's new facilities, risk associated with large-scale implementation ofthe Company's business plan, the ability to attract new customers, ability toincrease its product's applications, cost of raw materials, downturns in theChinese economy, and other information detailed from time to time in theCompany's filings and future filings with the United States Securities andExchange Commission. Investors are urged to consider these factors carefullyin evaluating the forward-looking statements herein and are cautioned not toplace undue reliance on such forward-looking statements, which are qualifiedin the
You May Also Like